Top

Breast Cancer Research and Treatment

Published in:

01-04-2018 | Clinical trial

^99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis

Authors: Jiwei Wang, Tie Fan, Yingjian He, Xue Chen, Zhaoqing Fan, Yuntao Xie, Tianfeng Wang, Jinfeng Li, Tao Ouyang

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Abstract

Purpose

This study aimed to determine the long-term prognosis of breast cancer patients with ^99mTc-rituximab for sentinel lymph node biopsy (SLNB).

Methods

A total of 2947 patients with negative sentinel lymph nodes (SLNs) omitting axillary lymph node dissection (ALND), treated between June 2005 and December 2013, were retrospectively analyzed. SLNB was performed prior to adjuvant therapy.

Results

After a median follow-up of 62 months, 22 cases of axillary recurrence (AR) were observed. The 5-year AR rate (ARR) was 0.7% [95% confidence interval (CI) 0.3–1.1%] and the 5-year relapse-free survival (RFS) was 95.2% (95% CI 94.4–96.0%). Multivariate analysis showed that abnormal axillary ultrasound with negative fine-needle aspiration (FNA) [hazard ratio (HR) 3.79, 95% CI 1.55–9.28; P = 0.004], not receiving radiotherapy (HR 4.38, 95% CI 1.47–13.05; P = 0.008), and age ≤ 40 years (HR 2.93, 95% CI 1.19–7.20; P = 0.020) were independent risk factors for AR.

Conclusions

ARR of SLNB-negative patients with ^99mTc-rituximab is low. Abnormal axillary ultrasound with negative FNA, not receiving radiotherapy, and age ≤ 40 years were prognostic factors for higher ARRs.

Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933. https://doi.org/10.1016/s1470-2045(10)70207-2 CrossRefPubMedPubMedCentral

Veronesi U, Viale G, Paganelli G et al (2010) Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 251(4):595–600. https://doi.org/10.1097/SLA.0b013e3181c0e92a CrossRefPubMed

Zavagno G, De Salvo GL, Scalco G et al (2008) A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 247(2):207–213. https://doi.org/10.1097/SLA.0b013e31812e6a73 CrossRefPubMed

Canavese G, Catturich A, Vecchio C et al (2009) Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 20(6):1001–1007. https://doi.org/10.1093/annonc/mdn746 CrossRefPubMed

Lyman GH, Temin S, Edge SB et al (2014) Sentinel lymph node biopsy for patients with early-stage breast cancer: american Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32(13):1365–1383. https://doi.org/10.1200/jco.2013.54.1177 CrossRefPubMed

Lyman GH, Somerfield MR, Bosserman LD et al. (2016) Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. JCO2016710947

Wang XJ, Lin BH, Yang Z et al (2006) Preliminary study on a new sentinel lymphoscintigraphy agent 99 mTc-Rituximab for breast patient. Zhonghua Zhong Liu Za Zhi 28(3):200–203PubMed

Pesek S, Ashikaga T, Krag LE et al (2012) The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg 36(9):2239–2251. https://doi.org/10.1007/s00268-012-1623-z CrossRefPubMedPubMedCentral

Wang X, Yang Z, Lin B et al (2016) Technetium-99 m-labeled rituximab for use as a specific tracer of sentinel lymph node biopsy: a translational research study. Oncotarget. https://doi.org/10.18632/oncotarget.9614

10.

Wallace AM, Han LK, Povoski SP et al (2013) Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol 20(8):2590–2599. https://doi.org/10.1245/s10434-013-2887-8 CrossRefPubMedPubMedCentral

11.

Sondak VK, King DW, Zager JS et al (2013) Combined analysis of phase III trials evaluating [(9)(9)mTc] tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol 20(2):680–688. https://doi.org/10.1245/s10434-012-2612-z CrossRefPubMed

12.

Li JF, Ouyang T, Wang XJ et al (2006) Preliminary study of new imaging agent, 99mTc-Rituximab, for sentinel lymph node biopsy of primary breast cancer. Zhonghua Wai Ke Za Zhi 44(9):600–602PubMed

13.

Pepels MJ, Vestjens JH, de Boer M et al (2011) Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review. Breast Cancer Res Treat 125(2):301–313. https://doi.org/10.1007/s10549-010-1210-7 CrossRefPubMed

14.

Veronesi U, Galimberti V, Paganelli G et al (2009) Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer 45(8):1381–1388. https://doi.org/10.1016/j.ejca.2008.11.041 CrossRefPubMed

15.

Galimberti V, Manika A, Maisonneuve P et al (2014) Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. Eur J Surg Oncol 40(10):1203–1208. https://doi.org/10.1016/j.ejso.2014.07.041 CrossRefPubMed

16.

van Wely BJ, van den Wildenberg FJ, Gobardhan P et al (2012) Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients. Eur J Surg Oncol 38(10):925–931. https://doi.org/10.1016/j.ejso.2012.04.016 CrossRefPubMed

17.

van Wely BJ, Teerenstra S, Schinagl DA et al (2011) Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy. Br J Surg 98(3):326–333. https://doi.org/10.1002/bjs.7360 CrossRefPubMed

18.

Giuliano AE, Ballman K, McCall L et al (2016) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the american college of surgeons oncology group (alliance) acosog z0011 randomized trial. Ann Surg 264(3):413–420. https://doi.org/10.1097/sla.0000000000001863 CrossRefPubMedPubMedCentral

19.

Chen HL, Zhou MQ, Tian W et al (2016) Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PLoS ONE 11(10):e0165409. https://doi.org/10.1371/journal.pone.0165409 CrossRefPubMedPubMedCentral

20.

Hanrahan EO, Valero V, Gonzalez-Angulo AM et al (2006) Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a, bN0M0): a review of the literature. J Clin Oncol 24(13):2113–2122. https://doi.org/10.1200/jco.2005.02.8035 CrossRefPubMed

21.

Houvenaeghel G, Classe JM, Garbay JR et al (2016) Survival impact and predictive factors of axillary recurrence after sentinel biopsy. Eur J Cancer 58:73–82. https://doi.org/10.1016/j.ejca.2016.01.019 CrossRefPubMed

22.

Kashiwagi S, Onoda N, Asano Y et al (2015) Ambulatory sentinel lymph node biopsy preceding neoadjuvant therapy in patients with operable breast cancer: a preliminary study. World J Surg Oncol 13:53. https://doi.org/10.1186/s12957-015-0471-3 CrossRefPubMedPubMedCentral

23.

Menard JP, Extra JM, Jacquemier J et al (2009) Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy. Eur J Surg Oncol 35(9):916–920. https://doi.org/10.1016/j.ejso.2008.11.002 CrossRefPubMed

Title: 99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis
Authors: Jiwei Wang
Tie Fan
Yingjian He
Xue Chen
Zhaoqing Fan
Yuntao Xie
Tianfeng Wang
Jinfeng Li
Tao Ouyang
Publication date: 01-04-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4591-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy

Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer

Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy

A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer

Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer